Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biontech Se ADR (BNTX)

156.49   5.51 (3.65%) 01-25 23:27
Open: 157.485 Pre. Close: 150.98
High: 166.5 Low: 152.5578
Volume: 4,071,003 Market Cap: 37,951M
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 166.783 - 167.58 167.58 - 168.303
Low: 150.703 - 151.581 151.581 - 152.377
Close: 155.035 - 156.487 156.487 - 157.805

Technical analysis

as of: 2022-01-25 4:22:35 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 278.53     One year: 353.13
Support: Support1: 135.13    Support2: 112.43
Resistance: Resistance1: 238.47    Resistance2: 302.34
Pivot: 191.34
Moving Average: MA(5): 154.63     MA(20): 204.93
MA(100): 272.42     MA(250): 230.73
MACD: MACD(12,26): -30.23     Signal(9): -25.52
Stochastic oscillator: %K(14,3): 12.08     %D(3): 6.08
RSI: RSI(14): 28.99
52-week: High: 464.00  Low: 90.29  Change(%): 33.8
Average Vol(K): 3-Month: 3578  10-Days: 3533

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
BNTX has closed above bottom band by 20.3%. Bollinger Bands are 23.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 25 Jan 2022
Where Will BioNTech SE - ADR (BNTX) Stock Go Next After It Is Down 4.62% in a Week? - InvestorsObserver

Fri, 21 Jan 2022
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021 - Entrepreneur

Wed, 19 Jan 2022
After Plunging 37.7% in 4 Weeks, Here's Why the Trend Might Reverse for BioNTech SE Sponsored ADR (BNTX) - Nasdaq

Thu, 13 Jan 2022
What's Going On With Moderna, BioNTech And Novavax Stock Today - Benzinga - Benzinga

Tue, 11 Jan 2022
New Strong Buy Stocks for January 11th - Entrepreneur

Mon, 10 Jan 2022
$BNTX BioNTech And Crescendo Biologics Announce Collaboration To Develop Multi-Specific Immunotherapies - CML News

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 243
Shares Float (M) 78
% Held by Insiders 66.88
% Held by Institutions 17.21
Shares Short (K) 2,160
Shares Short P. Month (K) 2,290

Stock Financials

EPS 31.970
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 35.650
Profit Margin 54.34
Operating Margin 74.25
Return on Assets (ttm) 81.6
Return on Equity (ttm) 155.5
Qtrly Rev. Growth 8918.2
Gross Profit (p.s.) -0.916
Sales Per Share 56.861
EBITDA (p.s.) 42.429
Qtrly Earnings Growth
Operating Cash Flow (M) 1,340
Levered Free Cash Flow (M) -55

Stock Valuations

PE Ratio 4.89
PEG Ratio
Price to Book value 4.39
Price to Sales 2.75
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.